PDE5: A new therapeutic target for lower urinary tract symptoms/ benign prostatic hyperplasia combined with erectile dysfunction / 中华男科学杂志
National Journal of Andrology
;
(12): 355-359, 2018.
Artículo
en Chino
| WPRIM
| ID: wpr-689750
ABSTRACT
Benign prostatic hyperplasia (BPH) with lower urinary tract symptoms (LUTS) is a common disease with frequent occurrence in elderly men, and its incidence shows a significant positive correlation with age. Evidence has confirmed that BPH/LUTS is closely related to erectile dysfunction (ED) and significantly affects the quality of life of elderly males. Phosphodiesterase 5 inhibitors (PDE5i) can improve both ED and BPH/LUTS of the patients and PDE5 is expected to be a new therapeutic target for BPH/LUTS with ED. This review explores the structure and function of PDE5 and the action mechanisms of PDE5i so as to provide a more effective strategy for the clinical treatment of BPH/LUTS with ED.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Hiperplasia Prostática
/
Calidad de Vida
/
Usos Terapéuticos
/
Quimioterapia
/
Quimioterapia Combinada
/
Inhibidores de Fosfodiesterasa 5
/
Síntomas del Sistema Urinario Inferior
/
Disfunción Eréctil
Tipo de estudio:
Estudio diagnóstico
Límite:
Anciano
/
Humanos
/
Masculino
Idioma:
Chino
Revista:
National Journal of Andrology
Año:
2018
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS